Nuvation Bio Shares Plunge 26% on High Ibtrozi Discontinuation Rates
NUVB has more than doubled off its 52-week low of $1.54.
Summary
Nuvation Bio's stock plunged 26% after the company disclosed higher-than-expected discontinuations for its lung-cancer drug, Ibtrozi, which is its sole product revenue source. This market reaction follows the company's Q4 and full-year 2025 earnings report released yesterday, which initially highlighted "robust" results and "strong commercial momentum." However, the market is now focusing on the operational detail of patient discontinuations, which were primarily from later-line populations. The company also reported an EPS miss ($0.11 loss vs. $0.08 expected) despite a revenue beat ($41.9M vs. $37.8M expected). High discontinuation rates for Ibtrozi raise concerns about the drug's long-term commercial viability and revenue growth trajectory, despite management's expectation for improvement as the drug moves up in the treatment paradigm. Investors will monitor future reports for trends in Ibtrozi discontinuation rates and the company's progress in shifting the drug's use to earlier treatment lines.
At the time of this announcement, NUVB was trading at $4.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.54 to $9.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.